TSC1 promotes B cell maturation but is dispensable for germinal center formation

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Ci, Xinxin ^a,b   Kuraoka, Masayuki ^a   Wang, Hongxia ^a,c   Carico, Zachary ^a   Hopper, Kristen ^a   Shin, Jinwook ^a   Deng, Xuming ^b   Qiu, Yirong ^c   Unniraman, Shyam ^a   Kelsoe, Garnett ^a   Zhong, Xiao Ping ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JILIN UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G2C; IMMUNOGLOBULIN G3; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; T LYMPHOCYTE ANTIGEN; TUBEROUS SCLEROSIS COMPLEX 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BIOACCUMULATION; CELL MATURATION; CELL SELECTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GERM CELL; IMMUNE SYSTEM; IMMUNIZATION; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ADAPTIVE IMMUNITY; ANIMAL; ANTIBODY PRODUCTION; GENETICS; GERMINAL CENTER; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; METABOLISM; PEYER PATCH; SPLEEN;

MUS;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; GERMINAL CENTER; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; PEYER'S PATCHES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SPLEEN; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84930647059     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127527     Document Type: Article

References (55)

1. Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol. 2001; 19:595-621. Epub 2001/03/13. doi: 10.1146/annurev.immunol.19.1.595 PMID: 11244048.
2. Loder F, Mutschler B, Ray RJ, Paige CJ, Sideras P, Torres R, et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med. 1999; 190(1):75-89. Epub 1999/08/03. PMID: 10429672; PubMed Central PMCID: PMC2195560.
3. Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol. 2002; 2(5):323-35. Epub 2002/05/30. doi: 10.1038/nri799 PMID: 12033738.
4. Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol. 2008; 20(2):149-57. Epub 2008/04/25. doi: 10.1016/j.coi.2008.03.014 PMID: 18434123; PubMed Central PMCID: PMC2532490.
5. Allman D, Srivastava B, Lindsley RC. Alternative routes to maturity: branch points and pathways for generating follicular and marginal zone B cells. Immunol Rev. 2004; 197:147-60. Epub 2004/02/14. PMID: 14962193.
6. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008; 8(1):22-33. Epub 2007/12/22. doi: 10.1038/nri2217 PMID: 18097447.
7. Gearhart PJ, Johnson ND, Douglas R, Hood L. IgG antibodies to phosphorylcholine exhibit more diversity than their IgM counterparts. Nature. 1981; 291(5810):29-34. Epub 1981/05/07. PMID: 7231520.
8. Kuraoka M, Liao D, Yang K, Allgood SD, Levesque MC, Kelsoe G, et al. Activation-induced cytidine deaminase expression and activity in the absence of germinal centers: insights into hyper-IgM syndrome. J Immunol. 2009; 183(5):3237-48. Epub 2009/08/12. doi: 10.4049/jimmunol.0901548 PMID: 19667096; PubMed Central PMCID: PMC2779701.
9. Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2012; 30:429-57. Epub 2012/01/10. doi: 10.1146/annurev-immunol-020711-075032 PMID: 22224772.
10. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. Epub 2012/04/17. doi: 10.1016/j.cell.2012.03.017 PMID: 22500797; PubMed Central PMCID: PMC3331679.
11. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007; 12(1):9-22. Epub 2007/07/07. doi: 10.1016/j.ccr.2007.05.008 PMID: 17613433.
12. Yang Q, Guan KL. Expanding mTOR signaling. Cell Res. 2007; 17(8):666-81. Epub 2007/08/08. doi: 10.1038/cr.2007.64 PMID: 17680028.
13. Astrinidis A, Cash TP, Hunter DS, Walker CL, Chernoff J, Henske EP. Tuberin, The tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene. 2002; 21(55):8470-6. Epub 2002/12/06. doi: 10.1038/sj.onc.1205962 PMID: 12466966.
14. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004; 14(14):1296-302. Epub 2004/07/23. doi: 10.1016/j.cub.2004.06.054 PMID: 15268862.
15. O'Brien TF, Zhong XP. The role and regulation of mTOR in T-lymphocyte function. Archivum immunologiae et therapiae experimentalis. 2012; 60(3):173-81. Epub 2012/04/10. doi: 10.1007/s00005-012-0171-4 PMID: 22484804.
16. Weichhart T, Saemann MD. The multiple facets of mTOR in immunity. Trends Immunol. 2009; 30(5):218-26. Epub 2009/04/14. doi: 10.1016/j.it.2009.02.002 PMID: 19362054.
17. Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol. 2012; 12(5):325-38. Epub 2012/04/21. doi: 10.1038/nri3198 PMID: 22517423; PubMed Central PMCID: PMC3417069.
18. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity. 2009; 30(6):832-44. Epub 2009/06/23. doi: 10.1016/j.immuni.2009.04.014 PMID: 19538929; PubMed Central PMCID: PMC2768135.
19. Lee K, Gudapati P, Dragovic S, Spencer C, Joyce S, Killeen N, et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity. 2010; 32(6):743-53. Epub 2010/07/14. doi: 10.1016/j.immuni.2010.06.002 PMID: 20620941; PubMed Central PMCID: PMC2911434.
20. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009; 460(7251):108-12. Epub 2009/06/23. doi: 10.1038/nature08155 PMID: 19543266; PubMed Central PMCID: PMC2710807.
21. + T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity. 2010; 32(1):67-78. Epub 2010/01/12. doi: 10.1016/j.immuni.2009.10.010 PMID: 20060330.
22. Sinclair LV, Finlay D, Feijoo C, Cornish GH, Gray A, Ager A, et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol. 2008; 9(5):513-21. Epub 2008/04/09. doi: 10.1038/ni.1603 PMID: 18391955; PubMed Central PMCID: PMC2857321.
23. Zeng H, Yang K, Cloer C, Neale G, Vogel P, Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature. 2013; 499(7459):485-90. Epub 2013/07/03. doi: 10.1038/nature12297 PMID: 23812589; PubMed Central PMCID: PMC3759242.
24. Shin J, Wang S, Deng W, Wu J, Gao J, Zhong XP. Mechanistic target of rapamycin complex 1 is critical for invariant natural killer T-cell development and effector function. Proc Natl Acad Sci U S A. 2014; 111(8):E776-83. Epub 2014/02/12. doi: 10.1073/pnas.1315435111 PMID: 24516149.
25. Zhang S, Readinger JA, DuBois W, Janka-Junttila M, Robinson R, Pruitt M, et al. Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood. 2011; 117(4):1228-38. Epub 2010/11/17. doi: 10.1182/blood-2010-05-287821 PMID: 21079150; PubMed Central PMCID: PMC3056471.
26. Lee K, Heffington L, Jellusova J, Nam KT, Raybuck A, Cho SH, et al. Requirement for Rictor in homeostasis and function of mature B lymphoid cells. Blood. 2013; 122(14):2369-79. Epub 2013/08/21. doi: 10.1182/blood-2013-01-477505 PMID: 23958952; PubMed Central PMCID: PMC3790507.
27. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002; 4(9):648-57. Epub 2002/08/13. doi: 10.1038/ncb839 PMID: 12172553.
28. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003; 13(15):1259-68. Epub 2003/08/09. PMID: 12906785.
29. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA. 2002; 99(21):13571-6. Epub 2002/09/25. doi: 10.1073/pnas.202476899 PMID: 12271141; PubMed Central PMCID: PMC129715.
30. Zhong XP, Shin J, Gorentla BK, O'Brien T, Srivatsan S, Xu L, et al. Receptor signaling in immune cell development and function. Immunol Res. 2011; 49(1-3):109-23. Epub 2010/12/04. doi: 10.1007/s12026-010-8175-9 PMID: 21128010; PubMed Central PMCID: PMC3193797.
31. Pan H, O'Brien TF, Zhang P, Zhong XP. The role of tuberous sclerosis complex 1 in regulating innate immunity. J Immunol. 2012; 188(8):3658-66. Epub 2012/03/14. doi: 10.4049/jimmunol.1102187 PMID: 22412198; PubMed Central PMCID: PMC3324625.
32. Shin J, Pan H, Zhong XP. Regulation of mast cell survival and function by tuberous sclerosis complex 1. Blood. 2012; 119(14):3306-14. Epub 2012/03/01. doi: 10.1182/blood-2011-05-353342 PMID: 22362037; PubMed Central PMCID: PMC3321856.
33. Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 2008; 28(12):4104-15. Epub 2008/04/16. doi: 10.1128/MCB.00289-08 PMID: 18411301; PubMed Central PMCID: PMC2423120.
34. Yang K, Neale G, Green DR, He W, Chi H. The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nat Immunol. 2011; 12(9):888-97. Epub 2011/07/19. doi: 10.1038/ni.2068 PMID: 21765414; PubMed Central PMCID: PMC3158818.
35. + T cell survival and homeostasis in mice. PLoS One. 2012; 7(2):e30592. Epub 2012/03/01. doi: 10.1371/journal.pone.0030592 PMID: 22363451; PubMed Central PMCID: PMC3283604.
36. Wu Q, Liu Y, Chen C, Ikenoue T, Qiao Y, Li CS, et al. The tuberous sclerosis complex-mammalian target of rapamycin pathway maintains the quiescence and survival of naive T cells. J Immunol. 2011; 187(3):1106-12. Epub 2011/06/29. doi: 10.4049/jimmunol.1003968 PMID: 21709159; PubMed Central PMCID: PMC3151493.
37. Xie DL, Wu J, Lou YL, Zhong XP. Tumor suppressor TSC1 is critical for T-cell anergy. Proc Natl Acad Sci USA. 2012; 109(35):14152-7. Epub 2012/08/15. doi: 10.1073/pnas.1119744109 PMID: 22891340; PubMed Central PMCID: PMC3435231.
38. Zhong XP. An expanded role of the tumor suppressor TSC1 in T cell tolerance. Cell Cycle. 2012; 11 (21):3909-10. Epub 2012/10/04. doi: 10.4161/cc.22235 PMID: 23032259; PubMed Central PMCID: PMC3507479.
39. Wu J, Shin J, Xie D, Wang H, Gao J, Zhong XP. Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity. J Immunol. 2014; 192(6):2643-50. Epub 2014/02/18. doi: 10.4049/jimmunol.1302076 PMID: 24532578; PubMed Central PMCID: PMC3965184.
40. Krishna S, Yang J, Wang H, Qiu Y, Zhong XP. Role of tumor suppressor TSC1 in regulating antigen-specific primary and memory CD8 T cell responses to bacterial infection. Infect Immun. 2014; 82(7):3045-57. Epub 2014/05/14. doi: 10.1128/IAI.01816-14 PMID: 24818661; PubMed Central PMCID: PMC4097607.
41. Wu J, Yang J, Yang K, Wang H, Gorentla B, Shin J, et al. iNKT cells require TSC1 for terminal maturation and effector lineage fate decisions. J Clin Invest. 2014. Epub 2014/03/13. doi: 10.1172/JCI69780 PMID: 24614103.
42. Park Y, Jin HS, Lopez J, Elly C, Kim G, Murai M, et al. TSC1 regulates the balance between effector and regulatory T cells. J Clin Invest. 2013; 123(12):5165-78. Epub 2013/11/26. doi: 10.1172/JCI69751 PMID: 24270422; PubMed Central PMCID: PMC3859395.
43. Chen H, Zhang L, Zhang H, Xiao Y, Shao L, Li H, et al. Disruption of TSC1/2 signaling complex reveals a checkpoint governing thymic CD4+ CD25+ Foxp3+ regulatory T-cell development in mice. FASEB J. 2013; 27(10):3979-90. Epub 2013/07/25. doi: 10.1096/fj.13-235408 PMID: 23882125.
44. Pan H, O'Brien TF, Wright G, Yang J, Shin J, Wright KL, et al. Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA. J Immunol. 2013; 191(2):699-707. Epub 2013/06/19. doi: 10.4049/jimmunol.1201443 PMID: 23776173; PubMed Central PMCID: PMC3702379.
45. Chen C, Liu Y, Liu R, Ikenoue T, Guan KL, Liu Y, et al. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med. 2008; 205(10):2397-408. Epub 2008/09/24. doi: 10.1084/jem.20081297 PMID: 18809716; PubMed Central PMCID: PMC2556783.
46. Benhamron S, Tirosh B. Direct activation of mTOR in B lymphocytes confers impairment in B-cell maturation andloss of marginal zone B cells. Eur J Immunol. 2011; 41(8):2390-6. Epub 2011/06/16. doi: 10.1002/eji.201041336 PMID: 21674478.
47. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N, et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet. 2002; 11(5):525-34. Epub 2002/03/05. PMID: 11875047.
48. Rickert RC, Roes J, Rajewsky K. B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. 1997; 25(6):1317-8. Epub 1997/03/15. PMID: 9092650; PubMed Central PMCID: PMC146582.
49. Shapiro-Shelef M, Lin KI, Savitsky D, Liao J, Calame K. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med. 2005; 202(11):1471-6. Epub 2005/11/30. doi: 10.1084/jem.20051611 PMID: 16314438; PubMed Central PMCID: PMC2213334.
50. Holl EK, O'Connor BP, Holl TM, Roney KE, Zimmermann AG, Jha S, et al. Plexin-D1 is a novel regulator of germinal centers and humoral immune responses. J Immunol. 2011; 186(10):5603-11. Epub 2011/04/06. doi: 10.4049/jimmunol.1003464 PMID: 21464091.
51. Han S, Dillon SR, Zheng B, Shimoda M, Schlissel MS, Kelsoe G. V(D)J recombinase activity in a subset of germinal center B lymphocytes. Science. 1997; 278(5336):301-5. Epub 1997/10/10. PMID: 9323211.
52. Odegard VH, Schatz DG. Targeting of somatic hypermutation. Nat Rev Immunol. 2006; 6(8):573-83. Epub 2006/07/27. doi: 10.1038/nri1896 PMID: 16868548.
53. Calamito M, Juntilla MM, Thomas M, Northrup DL, Rathmell J, Birnbaum MJ, et al. Akt1 and Akt2 promote peripheral B-cell maturation and survival. Blood. 2010; 115(20):4043-50. Epub 2010/01/01. doi: 10.1182/blood-2009-09-241638 PMID: 20042722; PubMed Central PMCID: PMC2875094.
54. Anzelon AN, Wu H, Rickert RC. Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol. 2003; 4(3):287-94. Epub 2003/02/04. doi: 10.1038/ni892 PMID: 12563260.
55. Chen J, Limon JJ, Blanc C, Peng SL, Fruman DA. Foxo1 regulates marginal zone B-cell development. Eur J Immunol. 2010; 40(7):1890-6. Epub 2010/05/08. doi: 10.1002/eji.200939817 PMID: 20449867; PubMed Central PMCID: PMC2926184.